NEVVI Medicare utilization intelligence

← back

MARKAN, YUDHISHTRAM.D. NPI 1891762019 Clinician

Hematology-Oncology · GLEN BURNIE, MD

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 47 years since medical school (class of 1979, self-reported to CMS)
Location GLEN BURNIE, MD · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 66 codes billed · 251,111 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
CHESAPEAKE UROLOGY ASSOCIATES LLC
2026
CHESAPEAKE ONCOLOGY HEMATOLOGY ASSOC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2026-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1627 Injection, granisetron, extended-release, 0.1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J0897 Injection, denosumab, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
80053 Blood test, comprehensive group of blood chemicals
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
J9190 Injection, fluorouracil, 500 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
J0640 Injection, leucovorin calcium, per 50 mg
82728 Ferritin (blood protein) level
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96375 Injection of additional new drug or substance into vein
83540 Iron level
82378 Carcinoembryonic antigen (cea) protein level
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J9045 Injection, carboplatin, 50 mg
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96523 Irrigation of implanted venous access drug delivery device
J3490 Unclassified drugs
83615 Lactate dehydrogenase (enzyme) level
96417 Administration of additional new drug or substance into vein, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J1200 Injection, diphenhydramine hcl, up to 50 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96411 Administration of additional new drug or substance into vein using push technique
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J7030 Infusion, normal saline solution , 1000 cc
84443 Blood test, thyroid stimulating hormone (tsh)
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
83735 Magnesium level
84153 Psa (prostate specific antigen) measurement, total
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96361 Infusion into a vein for hydration, each additional hour
80048 Blood test, basic group of blood chemicals (calcium, total)
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg
90661 Influenza vaccine, trivalent derived from cell cultures
G0008 Administration of influenza virus vaccine
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
96360 Infusion into a vein for hydration, 31-60 minutes
38222 Biopsy and aspiration of bone marrow sample for diagnosis
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.